Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;11(9):e1026.
doi: 10.1002/iid3.1026.

Dense fine speckled nuclear immunofluorescence: A mildly reassuring antinuclear antibody pattern meriting consideration

Affiliations

Dense fine speckled nuclear immunofluorescence: A mildly reassuring antinuclear antibody pattern meriting consideration

Aleksandra Fijałkowska et al. Immun Inflamm Dis. 2023 Sep.

Abstract

Introduction: Antinuclear antibodies (ANAs) are regarded as a hallmark of connective tissue diseases (CTDs) and play a key role in their diagnosis, but the value of some particular antibodies in management of patients and the disease prognosis is controversial. The mechanism underlying the production of ANAs in CTDs, other chronic inflammatory conditions and even in healthy people, is not completely elucidated. Anti-DFS70 antibodies connected with the dense fine speckled autoantigen of 70 kD, known as the lens epithelium-derived growth factor p75, are a subgroup of ANAs. Their presence and coexistence with other antibodies and their clinical significance are the matter of debate.

Methods: Based on literature data, the authors focused on current knowledge explaining the role of anti-DFS70 antibodies in selected CTDs.

Results: However, the literature data is ambiguous and does not fully support the validity of the anti-DFS70 assay for a specific CTD diagnosis. Most researchers claim that the presence of anti-DFS70 as the only one usually exclude the diagnosis of CTD. Nevertheless, its coexistence with other ANAs is not an excluding factor but has predictive value due to more favorable course of CTD. Such situations may also suggest an enhanced risk of the development of a CTD in the future.

Conclusions: Although more studies are needed in this field, it seems reasonable to ascertain the presence of anti-DFS70 in routine clinical practice.

Keywords: Sjögren's syndrome; anti-DFS70 antibody assay; antinuclear antibodies; connective tissue diseases; systemic lupus erythematosus; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
DSF70 Speckled pattern distributed throughout the interphase nucleus with characteristic heterogeneity in the size, brightness, and distribution of the speckles. Note some denser and looser areas of speckles (courtesy of Marzena Kraska‐Gacka).

Similar articles

References

    1. Peker BO, Şener AG, Tarhan EF, Kaya S. Investigation of anti‐DFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;38(12):3627‐3633. 10.1007/s10067-019-04730-y - DOI - PubMed
    1. Sanchez‐Hernandez ES, Ortiz‐Hernandez GL, Ochoa PT, et al. The nuclear dense fine speckled (DFS) immunofluorescence pattern: not all roads lead to DFS70/LEDGFp75. Diagnostics. 2023;13(2):222. 10.3390/diagnostics13020222 - DOI - PMC - PubMed
    1. Troelnikov A, Hender L, Lester S, Gordon TP, Hughes T, Beroukas D. The choice of anti‐LEDGF/DFS70 assay matters: a comparative study of six assays. Pathology. 2022;54(7):910‐916. 10.1016/j.pathol.2022.07.010 - DOI - PubMed
    1. Ochs RL, Mahler M, Basu A, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016;16(3):273‐293. 10.1007/s10238-015-0367-0 - DOI - PMC - PubMed
    1. Ge Q, Gu X, Yu W, et al. Antinuclear antibodies in healthy population: positive association with abnormal tissue metabolism, inflammation and immune dysfunction. Int Immunopharmacol. 2022;113(Pt A):109292. 10.1016/j.intimp.2022.109292 - DOI - PubMed